Preventing mucosal transmission of HIV is critical to halting the HIV epidemic. Novel approaches to preventing mucosal transmission are needed. Hyaluronic acid (HA) is a major extracellular component of mucosa and the primary ligand for the cell surface receptor CD44. CD44 enhances HIV infection of CD4 þ T cells, but the role of HA in this process is not clear. To study this, virions were generated with CD44 (HIV CD44 ) or without CD44 (HIV mock ). Exogenous HA reduced HIV infection of unstimulated CD4 þ T cells in a CD44-dependent manner. Conversely, hyaluronidase-mediated reduction of endogenous HA on the cell surface enhanced HIV binding to and infection of unstimulated CD4 þ T cells. Exogenous HA treatment reduced activation of protein kinase C alpha via CD44 on CD4 þ T cells during infection with HIV CD44 . These results reveal new roles for HA during the interaction of HIV with CD4 þ T cells that may be relevant to mucosal HIV transmission and could be exploitable as a future strategy to prevent HIV infection.
Prevention of HIV transmission is still the most direct way to stem the HIV/AIDS epidemic. 1 However, to date, large-scale clinical trials of vaccines to produce an HIV-specific antibody or a T-cell response to prevent HIV infection have been disappointing. 2, 3 As 80% of HIV infection occurs through sexual contact, 4 there is intense interest in the prevention of HIV mucosal transmission. To design a better strategy to prevent mucosal transmission of HIV, we need to more fully understand the mechanism of HIV mucosal transmission. 5 Mucosal tissues are the front-line defense against pathogen invasion and greatly impede HIV transmission. Studies using the simian immunodeficiency virus (SIV) rhesus macaque model demonstrate that the genital tract mucosal barrier limits exposure of CD4 þ T cells, dendritic cells and macrophages to the majority of the viral inoculum, and only a small number of infectious virions pass through the mucosal barrier to establish the infected founder population. 6, 7 These findings are confirmed by clinical studies showing that a small number of infectious virions breach the mucosal barrier to infect resting CD4 þ T cells, generating a clonal or oligoclonal founder population. 5, 8, 9 Mucosal integrity has an important role in HIV transmission, and mucosal inflammation can increase HIV transmission. [10] [11] [12] The mucosal tissues are composed of epithelial cells, extracellular matrix, interstitial cells and surface mucus. In addition to providing a full complement of host immune cells that variably facilitate or impede HIV infection, the mucosal surface also serves as a physical barrier to mucosal HIV invasion. Mucosal mucus can trap HIV virions 13 and reduce virion movement. 14 An acidic vaginal mucosal environment can decrease the rate of HIV sexual transmission. 15 How these effects on mucosal HIV transmission are mediated remains largely unknown. 5, 9 The surface of the mucosal layer is a scaffold with extracellular matrix; a major component of the extracellular matrix is hyaluronic acid (HA, or hyaluronan). HA is a large glycosaminoglycan that can be remodeled and degraded by hyaluronidase. On the surface of the cells, HA polymers extend up to 25 mm in length, forming pericellular coats. HA interaction with its receptors can induce cellular signaling and is involved in mucosal tissue homeostasis and maintenance of tissue integrity. [16] [17] [18] HA is also a regulator of immunity. HA interaction with its main receptor, CD44, regulates recruitment and extravasation of T cells into sites of inflammation 19, 20 and participates in the inflammatory process. 16, 21 HA interaction with CD44 can reduce cytokine production from macrophages in the setting of inflammation 22 and lowers protein kinase C alpha (PKCa) activity to decrease histamine release from leukemic cell lines. 23 There are reasons to believe that HA-CD44 receptor interactions may influence mucosal transmission of HIV. Clinical studies have found that mucosal integrity, activation of T cells and secretion of cytokines are each involved in mucosal HIV transmission, 5, 9 and each is modulated by HA-CD44 receptor binding. Studies have also reported that the primary HA receptor, CD44, is incorporated into HIV-1 virions 24, 25 and that CD44 on the HIV virion surface maintains its biological function, such as binding to HA. 26 Moreover, CD44 on HIV virions enhances HIV-1 infectivity for primary CD4 þ T cells. 27 However, the effect of HA on HIV-1 infectivity remains poorly understood. The main aim of this study was to assess the role of HA in HIV infection. We observed that exogenous HA reduced HIV infectivity when both virions and CD4 þ T cells expressed CD44. Effects were seen on both early infection events like viral binding and probably later events through reduction of PKCa activation, whereas treatment with hyaluronidase reduced endogenous HA thickness and enhanced susceptibility of CD4 þ T cells to infection.
RESULTS
Exogenous HA reduces HIV infectivity on unstimulated peripheral blood mononuclear cells, but only for virus bearing CD44 CD44 is found on HIV virions from either peripheral blood mononuclear cell (PBMC) cultures 24 or directly in patient plasma. 25 In contrast, 293T cells do not express appreciable levels of endogenous CD44. 27 Transfection of an expression vector containing CD44 complementary DNA (cDNA) from donor CD4 T cells resulted in CD44 protein expression in 293T cells (Supplementary Figure 1) , and Coulter) and bottom is the amount of HIV-p24 in the supernatant. Exogenous HA reduced HIV-p24 staining in CD44-transfected Jurkat cells infected with HIV CD44 , but not HIV mock . Exogenous HA had no effect on HIV-p24 staining when either HIV CD44 or HIV mock were used to infect Jurkat-E6.1 cells transfected with empty vector. Viral production was assessed by measurement of p24 in the supernatant. The effects of HA were analogous to those seen with intracellular staining for p24 in c. (Data in a are mean ± s.e.m. of triplicate samples and representative of three independent experiments, whereas data in b and c are from duplicate samples and representative of two independent experiments.) Figure 3) . Both viral stocks (HIV CD44 and HIV mock ) were tested on the reporter T cell line M7-Lue, which contains the luciferase gene under the control of the HIV long terminal repeat (LTR), providing a measure of infectivity. 31 In the presence of 10% fetal calf serum (FCS), viral stock containing CD44 (HIV CD44 ) demonstrated higher infectivity than HIV without CD44 (HIV mock ) in both M7-lue cell line (Supplementary Figure 4) and primary CD4 T cells (Supplementary Figure 5) . HIV produced from 293T cells cotransfected with CD44 (HIV CD44 ) has a similar infectivity compared with HIV produced by PBMCs (HIV PMBC ). This was not true for HIV generated from 293T cells without CD44 (HIV mock ) (Supplementary Figure 6) . Reports have indicated that FCS not only contains HA but it can also influence HA synthesis 32 and hyaluronidase activity. 33 To limit the confounding effects of FCS during the study of HA effects on HIV infection, we removed FCS when the cells inoculated with HIV. This resulted in reduced infectivity of viral stocks irrespective of virion CD44 expression (Supplementary Figure 7) . Earlier studies reported that exogenous HA could interrupt T-cell rolling and impede extravasation of T cells into an inflamed site through interactions with CD44. 19 To study whether exogenous HA can impact HIV infectivity, M7-Lue cells were treated with exogenous HA for 1 h, then inoculated with HIV CD44 or HIV mock produced from 293T cells and normalized by p24. HIV infectivity was measured at day 3 post infection by luciferase activity as relative light units. Exogenous HA reduced infectivity of HIV CD44 significantly but had no effect on the infectivity of HIV mock (Figure 1a ). This inhibitory effect of exogenous HA for HIV containing CD44 was confirmed in experiments with HIV produced from PBMCs (HIV PMBC ), which contain CD44. 25, 26 The reduction of infectivity of HIV by HA was dosage dependent (Figure 1b) .
To further confirm that exogenous HA treatment can reduce infectivity of HIV containing CD44, unstimulated, primary PBMCs from healthy donors were treated with exogenous HA, and then inoculated with viral stocks of HIV CD44 or HIV mock normalized by p24, then stimulated with phytomeagglutinin (PHA) and IL-2 for 24 h. HIV infectivity was assessed by measurement of supernatant HIV-1 p24 7 days post infection. Exogenous HA treatment significantly reduced HIV-1 p24 production during HIV CD44 infection, but had no impact on p24 production during HIV mock infection (Figure 1c) .
Because exogenous HA was added before HIV infection, we attempted to distinguish effects of HA on binding vs entry by using the entry inhibitor enfuvirtide (T-20). 34 Unstimulated, primary PBMCs were treated with exogenous HA for 1 h, then exposed to an equivalent inoculum by p24 of HIV CD44 or HIV mock for 5 h in the presence of 10 mg ml À1 of enfuvirtide (T-20). Afterwards, the cells were extensively washed, and the cellular HIV RNA was measured. Exogenous HA treatment significantly reduced cell surface HIV RNA 
CD44 on recipient cells is involved in exogenous HA's reduction of HIV infection
Although CD44 is the principal receptor for HA, HA also binds to other receptors on the cell surface, such as the receptor for hyaluronan-mediated motility (RHAMM), tumor necrosis factor (TNF)-stimulated gene-6/TNFa-induced protein six (TSG-6), lymphatic vessel endothelial HA receptor (LYVE-1), hyaluronan receptor for endocytosis (HARE), liver endothelial cell clearance receptor (LEC receptor) and TLR-4. 16, 17 To assess whether CD44 on the target cell is required to reveal the inhibitory effect of exogenous HA on HIV infectivity, a cell line lacking expression of the CD44, the Jurkat-E6.1 cell line 35 was studied. Jurkat-E6.1 cells were treated with exogenous HA before exposure to either HIV CD44 or HIV mock normalized by p24. HIV infectivity was assessed by measuring HIV-1 p24 production on day 7 post infection. Exogenous HA treatment had no impact on production of HIV-1 p24 for either HIV CD44 or HIV mock (Figure 2a) . Next, Jurkat-E6.1 cells were transfected with either the CD44 expression vector or empty vector (pcDNA3.1). At 3 days post transfection, the cells were examined by flow cytometry (fluorescence-activated cell sorting) after staining with anti-human CD44 antibody. Fifty-three percent of the cells that were transfected with the CD44 expression vector showed CD44 protein expression in the cells (Figure 2b ), but CD44 staining was absent in cells transfected with the empty vector. Next, both CD44-transfected and empty vector-transfected Jurkat-E6.1 cells were treated with exogenous HA before infection with either HIV CD44 or HIV mock normalized by p24; HIV infectivity was assessed by measuring HIV-1 p24 intracellular staining, and HIV-1 p24 on day 3 post infection. Exogenous HA reduced HIV-p24 intracellular staining and HIV-p24 production of HIV CD44 but not HIV mock in CD44-transfected E6.1 cells, whereas HA did not affect the ability of either virus to infect empty vector-transfected Jurkat-E6.1 cells (Figure 2c,  Supplementary Figure 8 ). These data indicate that CD44 expression on target cells is also required for exogenous HA to reduce infection by HIV CD44 .
Hyaluronidase treatment can enhance HIV CD44 infectivity on unstimulated CD4 þ T cells Endogenous HA has been observed to form a cushion on the cell surface, to have an anti-adhesive role 18 and to impede ligand access to cell surface receptors. 36 Hyaluronidase treatment can reduce endogenous HA from the cell surface, thus promoting cell-cell contact. 17 To determine whether endogenous HA on cell surfaces has an effect on HIV infection, M7-Lue cells were treated with hyaluronidase and then exposed to p24-equivalent inocula of HIV CD44 or HIV mock . HIV infectivity was assessed on day 3 post infection by measuring luciferase activity. Hyaluronidase treatment significantly enhanced infectivity of HIV CD44 ; however, this enhancement was reduced when exogenous HA was added. In contrast, hyaluronidase treatment had no effect on infectivity of HIV mock (Figure 3a) . This latter observation indicates that the inhibitory effect of HA for HIV infectivity is not simply through nonspecific steric hindrance.
In vivo studies of acute HIV and SIV infection demonstrate that virus initially targets resting CD4 þ T cells and establishes an infected founder population during mucosal transmission. 5, 8, 9 Hyaluronidase is highly activated during sexual intercourse as well as inflammation. [16] [17] [18] Our initial experiments showed that exogenous HA reduced HIV infection of unstimulated PBMCs. Thus, we studied the impact of hyaluronidase treatment on HIV infection of primary unstimulated CD4 þ T cells. Healthy donor, unstimulated, primary CD4 þ T cells were treated with hyaluronidase before inoculation with an equivalent input (by p24) of either HIV CD44 or HIV mock , then stimulated with PHA and interleukin (IL)-2 for 24 h. At day 7 post infection, infectivity was assessed by measurement of HIV-1 p24 in culture supernatants. Consistent with the ability of endogenous HA to inhibit HIV infection, hyaluronidase treatment significantly increased HIV CD44 infection of unstimulated CD4 þ T cells, but this enhancement could be completely reversed by addition of exogenous HA. However, hyaluronidase treatment had no effect on infectivity of HIV mock (Figure 3b ). These results indicate that hyaluronidase treatment renders unstimulated CD4 þ T cells more susceptible to HIV CD44 infection, possibly through reduction of cell surface HA.
Hyaluronidase treatment reduces the thickness of endogenous HA on unstimulated CD4 þ T-cell surface and enhances HIV binding Next, we investigated how hyaluronidase treatment impacts endogenous HA on the surface of unstimulated CD4 þ T cells. Unstimulated, primary CD4 þ T cells were treated with hyaluronidase, stained with biotinylated hyaluronan-binding protein 37 and studied using laser scanning microscopy Z-stack projections (Supplementary Figure 9) . Hyaluronidase treatment significantly reduced endogenous HA thickness on surface of the cells (Figures 4a-c) . This conclusion was corroborated by flow cytometry, which revealed that hyaluronidase treatment did not reduce the numbers of HA-positive cells (Figure 4d ), but significantly reduced the mean fluorescence intensity of HA staining (Figure 4e ). Because the thickness of endogenous HA has been postulated to prevent ligand binding to cognate receptors on the surface of T cells 36 and hyaluronidase treatment enhanced infectivity of HIV CD44 , we hypothesized that hyaluronidasemediated reduction of HA on the cell surface may enhance HIV binding. To test this hypothesis, unstimulated, primary CD4 þ T cells were treated with hyaluronidase and then incubated with HIV PBMC in the presence 10 mg ml À1 of the peptide fusion inhibitor T-20 32 for 5 h. Cells were washed five times to remove unbound HIV, stained with anti-HIV-1 p24 antibody and assessed by flow cytometry. 15.4% of hyaluronidase-treated cells stained positive for HIV-p24 (Figure 4f ), compared with only 3% of untreated cells (Po0.001) (Figure 4g ). These data indicate that endogenous HA on the cell surface can modulate HIV PBMC binding to unstimulated CD4 þ T cells.
PKCa signaling is important for reduction of HIV CD44 infection of unstimulated CD4 þ T cells by exogenous HA
Others have reported that interaction of exogenous HA with CD44 can reduce PKCa activation, 23 that PKCa has a critical role in HIV infectivity 38 and that the selective PKCa inhibitor 'Gö6976' can inhibit HIV infection. 39 To further investigate the role of PKCa in HA-CD44 modulation of HIV infectivity, M7-Lue cells were treated with Gö6976, dimethylsulphoxide (DMSO) or exogenous HA, then incubated with either HIV CD44 or HIV mock normalized by p24. HIV infectivity was assessed on day 3 post infection by measurement of luciferase activity. Gö6976 significantly reduced infectivity of HIV CD44 compared with the DMSO control, and the magnitude of this reduction was comparable to exogenous HA treatment. However, Gö6976 had no impact on the infectivity of HIV mock (Figure 5a) . Next, unstimulated, primary CD4 þ T cells from healthy controls were first treated with either Gö6976 or exogenous HA, then exposed for 5 h to either HIV CD44 or HIV mock normalized by p24. The toxicity of these treatments on the primary unstimulated CD4 þ T cells was evaluated using the ViaCount assay (Guava, Millipore, Billercia, MA, USA), and neither cell number nor viability was affected (Supplementary Figure 10) . The infectivity of HIV was assessed 7 days post infection by measurement of HIV-1 p24 in the supernatant. As expected, both Gö6976 and exogenous HA significantly reduced infectivity of HIV CD44 , but had no effect on infectivity of HIV mock (Figure 5b) . These results suggest that CD44 is involved in reduction of HIV infection by both Gö6976 and exogenous HA and that both treatments have a similar effect on HIV infection.
From these results, we hypothesize that reduction of infectivity of HIV CD44 by exogenous HA may involve the PKCa signaling pathways distal to CD44. To test this hypothesis, we evaluated PKCa phosphorylation, which corresponds to activation of PKCa, 23, 40 in unstimulated CD4 þ T cells treated with exogenous HA and exposed to HIV. Following treatment with exogenous HA and exposure to HIV, CD4 þ T cells were lysed and cellular proteins were extracted, coimmunoprecipitated with anti-CD44 antibody and analyzed using western blot. Treatment with exogenous HA had no effect on the amount of total PKCa protein in any condition (Figure 5c ), but phosphorylated PKCa was reduced following exogenous HA treatment, and the ratio of phosphorylated PKCa/PKCa was significantly reduced in exogenous HA-treated unstimulated CD4 þ T cells infected with HIV CD44 (Figure 5d ). These results suggest that reduction of HIV CD44 infectivity of unstimulated CD4 T cells by exogenous HA is mediated by inhibition of PKCa activation.
DISCUSSION
Devising more effective interventions to prevent mucosal HIV transmission will require a deeper understanding of the interplay between virus and target cells in the mucosal environment. Studies of both human and rhesus macaque models indicate that mucosal tissues provide multiple mechanisms to prevent HIV and SIV infection, including physical barriers and innate and adaptive immune responses. 5, 9 However, a small amount of HIV-1 and SIV can penetrate the mucosal barrier, gaining access to the submucosa and the initial recipient cell targets, which appear to be predominantly resting CD4 þ T cells. 8 Details of the interaction of HIV and SIV with resting CD4 þ T cells in the submucosa are not fully understood. 5, 9 In this study, we show for the first time that endogenous HA on unstimulated CD4 þ T cells is an obstacle for HIV infection and that hyaluronidase treatment can reduce endogenous HA, increase binding of HIV particles and enhance HIV infectivity. Furthermore, addition of exogenous HA at 100 mg ml À1 , the concentration of HA in human epidermis, 41 reduces HIV infectivity on unstimulated CD4 þ T cells. These data collectively argue that HA interferes with HIV infection during early stage, perhaps by directly impacting the interactions between CD44 and other molecules, or altering the distribution and/or activation status of local CD4 þ T cells, thus reducing targets that are needed for efficient transmission.
HA is the main component of the extra cellular matrix in the mucosal tissue. The main receptor for HA, CD44, is highly expressed in all cells, including CD4 þ T cells, and in mucosal tissues, especially those along the reproductive tract. 18, 42 HA interactions with CD44 are involved in mucosal immunity and participate in mucosal inflammation. 16, 21 It has been reported that exogenous HA can interfere with interaction of endogenous HA with CD44, limiting recruitment of T cells by reducing T-cell adhesion, 43 preventing T-cell rolling and inhibiting T-cell extravasation into an inflamed site. 19, 20 Other studies identify the recruitment of T cells into submucosa as important and necessary for mucosal HIV transmission. 5, 9 Our study demonstrates that exogenous HA reduces HIV infection of unstimulated PBMCs and unstimulated CD4 þ T cells and that this reduction of HIV infectivity is CD44 dependent. This inhibitory effect of HA was only observed when both HIV virions (HIV CD44 and HIV PBMC ) and recipient cells (Figure 2c) were CD44 þ . These results indicate that exogenous HA may reduce HIV infectivity by interfering with interactions between CD44 on HIV virions, endogenous HA (or other CD44 ligands) and CD44 on unstimulated CD4 þ T cells.
Others have reported that the endogenous HA coat on the surface of cells can prevent extraneous or indiscriminant ligand binding 18 and can prevent infection with Newcastle disease virus, vesicular stomatitis virus and rubella virus. Reducing the thickness of HA on the cell surface by hyaluronidase treatment can make target cells more susceptible to Newcastle disease virus, vesicular stomatitis virus and rubella virus infection. 44 We also observed that treatment of unstimulated CD4 þ T cells with hyaluronidase reduced the thickness of endogenous HA on the cell surface, allowing more HIV particles to bind (Figures 4c and d) , an effect that could be reversed by the addition of exogenous HA (Figure 3b ). Although these experimental results suggest that the inhibitory effects of HA on HIV infection occur at least in part at an early stage of the viral life cycle, including effects localizable to viral binding, further work is needed.
Interactions of HA with CD44 induce cellular signaling and regulate immune responses. 21 Others have observed that exogenous HA can reduce PKCa activity through CD44 23 to decrease expression of inflammatory regulators such as TNFa, IL-6, IL-18 and MMP-7. 45 PKCa is a classic isoform of PKC that is highly expressed in CD4 T cells. 46 PKCa and CD44 are localized in lipid microdomains (lipid rafts), 47 and HIV engagement with CD4 in lipid rafts is required for HIV infection. 48, 49 In turn, PKCa has been implicated as important for HIV infection, 38, 39 and Gö6976, a PKCa selective inhibitor, has been observed to reduce HIV infection. 39 This study is the first to show that virion CD44 is necessary for the reduction of HIV infectivity by Gö6976 and that Gö6976 treatment has an effect analogous to treatment with exogenous HA (Figures 5a and b) . This finding is compatible with a model where PKCa signaling is triggered by bridging of virion and cell surface CD44 by multivalent ligands. Our findings are reminiscent of the report by Chang et al. 50 that alpha-defensin-1 reduces HIV infectivity through decreased cellular phosphorylation of PKC, but not the amount of PKC protein. These investigators further determined that blocking phosphorylation of PKC resulted in inhibitory effects at later stages of the viral life cycle, including nuclear import and viral transcription. Such effects therefore represent at least a second, later stage in the viral life cycle that can be modulated by manipulating HA-CD44 interactions.
These findings are also similar to other recent data showing that anti-CD44 antibody beads enhance HIV infection only for HIV produced by PBMC, but not for HIV produced by 293T cells. 27 Under some conditions, different HA fragments are known to mediate CD44 interactions that augment T-cell activation. 21 In the current work, a commercial source of HA was used, as has been reported by many other investigators. 19, 34, 43 Although several experiments were performed with different sizes of HA (both high and low molecular weight), we did not observe consistent differences, but rather found that all sizes of exogenous HA inhibited HIV infection under the conditions tested (Supplementary Figure 11) . One possible effect of exogenous HA regardless of size may be its ability to compete with ligands (perhaps including some natural species of HA) that bind to CD44. We also observed that exogenous HA reduced HIV infectivity in unstimulated CD4 þ T cells to a degree greater than that observed in stimulated CD4 þ T cells (Supplementary Figures 12 and 13) . In such a model, excess exogenous HA may disrupt the optimal stoichiometry necessary for endogenous ligands to bind and bridge CD44, an effect that may be more important for the infection of resting CD4 T cells.
It is notable that HA, hyaluronidase and CD44 are all highly expressed and have important roles in maintaining the integrity and function of the mucosal tissue along the reproductive tract.
Hyaluronidase is also a major constituent of semen. 42 Both HA and hyaluronidase are highly upregulated during sexual intercourse as well as inflammation. 18 The processes of reproductive fertilization and HIV transmission intersect at many levels anatomically and functionally. Both involve the reproductive tract and permissiveness of mucosal tissue and surface barriers. Clinical studies have demonstrated that inflammation in the mucosal tissue can facilitate HIV transmission, 51 and that transmission rates are higher for HIV in semen compared with blood. 52 The identification of topical agents that can be applied to mucosal surfaces to prevent mucosal HIV transmission has been identified as a priority area for research and development in the effort to control the HIV/AIDS epidemic. 53 In summary, HA present on the surface of unstimulated CD4 þ T cells can influence HIV infection. Both HA and hyaluronidase have well-described roles in reproductive and inflammatory processes. Our data now show that the status of the HA coat may have an important role in the initial interaction of HIV virions with resting CD4 þ T cells, a feature that may be particularly relevant for mucosal HIV transmission. Intriguingly, exogenous HA appears to block HIV engagement and infection of target cells. Furthermore, HA interactions with virion and cell surface CD44 modulate PKCa activation and may have additional inhibitory effects on later stages of the viral life cycle. HA is a non-immunogenic natural biopolymer that has been used in a variety of clinical applications. These findings should be further explored in vivo and, if confirmed, could lead to the development of novel interventions to reduce HIV mucosal transmission.
METHODS

CD44 gene construction
Cloning of CD44 gene. A cDNA of the standard isoform of human CD44 was generated from RNA extracted from healthy donor CD4 T cells using SuperScript III Reverse Transcriptase (Life Technologies, Carlsbad, CA, USA) according the manufacturer's instructions and amplified using Platinum TaqDNA High Fidelity Polymerase (Life Technologies). Oligonucleotides used in reverse-transcription PCR were 5-CD44 (5 0 -CAGCCTCTGCCAGGTTCGG TCCGCCATCCTCG-3 0 ) and 3-CD44 (5 0 -TGAAGATCGAAGAAGTACAGATA TTTATTATG-3 0 ). The CD44 gene was cloned into pcDNA3.1/V5-His TOPO TA Expression vector (Life Technologies). The CD44 expression plasmid was purified and sequenced, and the CD44 clone was verified to be a perfect match to the standard isoform of human CD44 (GenBank AY101192.1).
Isolation of PBMCs and CD4 T cells from healthy donors
PBMCs were isolated from healthy donors as previously published, 31 and CD4 þ T cells were isolated from PBMCs using the EasySep Human CD4 þ T cell Enrichment kit (STEMCell, Vancouver, BC, Canada) according to the manufacturer's instructions.
Generation of HIV virus stock with or without CD44 from 293T cells and from PBMCs
Viral stock generated from 293T cells. 293T cells (ATCC, Manassas, VA, USA) were cultured in complete Dulbecco's modified Eagle's medium (Life Technologies) supplemented with penicillin (50 U ml À1 ), streptomycin (50 mg ml À1 ), 2 mM of L-glutamine (Life Technologies) and 10% heat-inactivated FCS (Sigma, St Louis, MO, USA), then cotransfected with 10 mg of pNL4-3 (NIH AIDS Research and Reference Reagent Program) and 5 mg CD44 plasmid (to generate HIV CD44 ), or with empty pcDNA3.1/V5-His TOPO TA Expression vector (to make HIV MOCK ) using FuGENE HD Transfection Reagent (Roche, Indianapolis, IN, USA) according to the manufacturer's instructions. Three days later, the supernatant was collected and HIV production was assessed using an HIV-1 p24 ELISA assay (PerkinElmer, Waltham, MA, USA).
HIV viral stock generated from PBMCs. Isolated PBMCs were stimulated with 3 mg ml À1 of PHA-M (Roche) and 20 U ml À1 of human-IL 2 (hIL-2; Roche) for 3 days; viral supernatant from transfection of 293T cells was used to infect pooled mixed stimulated PBMCs prepared from two healthy donors. The supernatant from HIV-infected PBMCs was collected at day 7 and day 11. Viral titers were determined by HIV-1 p24 ELISA (PerkinElmer).
Reduction of HA from cell surface
A total of 1 Â 10 6 ml À1 of unstimulated CD4 þ T cells or M7-lue cells were washed three times in RPMI without FCS and incubated in RPMI with 12 U ml À1 of hyaluronidase (Sigma) 19 for 60 min, followed by removal of supernatant and three washes with RPMI without FCS.
Co-immunoprecipitation with CD44 western blotting
A total of 2 Â 10 6 unstimulated healthy donor CD4 þ T cells were washed twice with cold phosphate-buffered saline and lysed using the Mammalian Cell Lysis kit (Sigma). The lysates were centrifuged at 4 1C for 10 min at 12 000 g to pellet cellular debris, and the clarified lysate was transferred to a fresh pre-chilled tube. Lysates were precleared by incubation with protein A/Sepharose (Sigma) for 1 h at 4 1C, subjected to immunoprecipitation with anti-CD44 (R&D systems, Minneapolis, MN, USA) overnight at 4 1C, then treated with 50 ml of protein G/ Sepharose (Sigma) for 2 h. The immunoprecipitates were washed 10 times with 1 ml of cold wash buffer (lysis buffer plus 0.5 M NaCl), then eluted from the protein G/Sepharose using 50 ml of elution buffer (1 M glycine, 0.25 M NaCl, pH 2.8). The Eluate was neutralized by 2 ml of 1 M Tris-Cl (pH 9.5), then subjected to10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane. The membrane was treated with blocking buffer (5% fat-free milk, 50 mM Tris-HCl (pH 7.5), 0.2 M NaCl and 0.2% volume Tween-20), then incubated overnight at 4 1C in blocking buffer containing either 1:250 dilution of antibody to PKCa (Santa Cruz Biotech, Santa Cruz, CA, USA) or antibody to phosphoryated-PKCa (Santa Cruz Biotech). Detection was performed using goat anti-mouse immunoglobulin G (IgG)-conjugated horseradish peroxidase (Sigma) and FATDAB tablets (Sigma). The bands were analyzed using Quantity One 1-D analysis Software (Bio-Rad, Hercules, CA, USA).
Staining HA and HIV (p24) on unstimulated CD4 þ T cells HA staining. We adapted a method from Lin 37 to stain HA on the unstimulated CD4 þ T cell surface. Unstimulated CD4 þ T cells were fixed by acid-formalin-ethanol and stained with biotinylated hyaluronan-binding protein (Calbiochem, Gibbstown, NJ, USA) overnight, then stained with Alexa488-streptavidin (Life Technologies) for 2 h. HA staining was measured by two methods: laser scanning microscopy and flow cytometry (fluorescenceactivated cell sorting). For laser scanning microscopy analysis, the cells were further stained, cell membranes were stained with Texas Red (Life Technologies) and nuclei stained with DAPI (4,6-diamidino-2-phenylindole; Life Technologies). LSM510 META laser scanning microscope (Carl Zeiss Microimaging Inc., Thornwood, NY, USA) was used to scan the cells with Z-stack projections. For fluorescence-activated cell sorting analysis, 50 000 HAstained cells were analyzed by EasyCyte6HT-2L (Millipore, Billercia, MA, USA).
HIV staining. Unstimulated CD4 þ T cells were incubated with HIV for 5 h, fixed with 2% formaldehyde and incubated with mouse anti-HIV-1 p24 antibody at 4 1C overnight, then stained with donkey anti-mouse IgG antibody conjugated with Alexa Fluor647 (Life Technologies) for 2 h. The HIV-1-p24-positive cells were measured by flow cytometry (fluorescence-activated cell sorting), 50 000 cells from each condition were analyzed by EasyCyte6HT-2L (Millipore).
Assays for HIV infection
M7-lue cell (5.25.EGFP.Lue.M7 cell, a gift from Dr David Montefiori (Duke University) and Dr Ned Landau (NYU)). A total of 1 Â 10 6 cells were washed with complete RPMI without FCS, then treated with study reagents, inoculated with 1000 pg HIV-p24 of HIV for 5 h, washed three times with complete RPMI and resuspended in complete RPMI. HIV infectivity was measured by using Bright-Glo Luciferase assay system (Promega, Madison, WI, USA) and measured with a plate reader (VICTOR3; PerkinElmer) at 3 days post infection. 31 The luciferase activity is presented as relative light units.
Jurkat (E6.1) cell (NIH AIDS Research and Reference Reagent Program).
For untransfected Jurkat cells, HIV infection conditions were the same as for the M7-Lue cell line, but HIV infectivity was measured by HIV-1 p24 production at 7 days post infection using the HIV-1p24 ELISA kit (PerkinElmer). For CD44 À or empty vector-transfected Jurkat cells, after 3 days of transfection, the cells were infected with 5 ng of HIV-p24 for 5 h, then washed three times with complete RPMI, resuspended in complete RPMI and cultured for 3 days. These cells were analyzed for HIV infection by two methods: first, by intracellular staining for HIV-p24 (KC-57RD1-PE; Beckman Coulter, Fullerton, CA, USA) and CD44 (anti-huCD44-APC; R&D system); and second, measuring HIV-1 p24 in the supernatant by p24 ELISA (PerkinElmer).
Unstimulated CD4 þ T cells and unstimulated PBMCs. A total of 1 Â 10 6 healthy donor unstimulated cells were washed with RPMI without FCS, treated with different reagents, inoculated with 1000 pg HIV-p24 of HIV for 5 h, washed three times with complete RPMI, resuspended in complete RPMI with 5 mg of PHA-M and 20 U of hIL-2 for 24 h, washed three times with completed RPMI and finally resuspended in completed RPMI with 20 U of hIL-2. HIV infectivity was measured by HIV-1 p24 production in supernatant at day 7 post infection by using the HIV-1p24 ELISA kit (PerkinElmer).
Measurement of cell-associated HIV RNA
Cellular RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and treated with DNase (Qiagen). RNA concentrations were measured using a ND-1000 Spectrophotometer (NanoDrop, Thermo Scientific, Wilmington, DE, USA). HIV RNA copy numbers were measured using a locked nucleic acid Taqman assay. Briefly, we performed a single-tube, one-step assay using 12.5 ml of TaqMmanRNA-to-CT-1STEP KIT (Life Technologies), 7. 
